Want to see SE:PILA full AI Analyst Report?
Top Page
PILA PHARMA AB
(PILA)
Select Model
Select Model
Rating:52Neutral
Price Target:
kr2.00
▼(-9.09% Downside)
Action:Reiterated
Date:09/15/26
The score is held back primarily by weak financial performance (persistent large losses and ongoing cash burn). Technicals are a clear positive with strong momentum above major moving averages, but valuation remains pressured by negative earnings and no dividend support.
Positive Factors
Debt-free balance sheet
A debt-free balance sheet reduces interest obligations and refinancing exposure, giving PILA greater financial flexibility while it develops its pipeline. The increase in equity to 14.8m in 2025 also supports solvency, although continued losses could weaken that cushion over time.
Negative Factors
Persistent cash burn
Persistent negative operating and free cash flow indicates that PILA is not yet funding its activities internally. Continued burn may require external financing before losses narrow, creating dilution or funding pressure and limiting the company’s flexibility to advance its development programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free balance sheet reduces interest obligations and refinancing exposure, giving PILA greater financial flexibility while it develops its pipeline. The increase in equity to 14.8m in 2025 also supports solvency, although continued losses could weaken that cushion over time.
Read all positive factors
PILA PHARMA AB (PILA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr89.77M
Dividend YieldN/A
Average Volume (3M)123.12K
Price to Earnings (P/E)―
Beta (1Y)0.10
Revenue Growth-71.19%
EPS Growth-23.18%
CountrySE
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.45
Shares Outstanding45,682,120
10 Day Avg. Volume182,871
30 Day Avg. Volume123,120
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)4.82
Price to Sales (P/S)63.25
P/FCF Ratio-7.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.38
Revenue Forecast (FY)N/A
PILA PHARMA AB Business Overview & Revenue Model
Company Description
Based in Sweden, PILA PHARMA AB (publ) is a pharmaceutical firm actively engaged in clinical development. The company's principal drug, XEN-D0501, is a TRPV1 antagonist which has successfully completed two phase 2a clinical studies aimed at treati...
How the Company Makes Money
As a clinical-stage pharmaceutical company, PILA PHARMA AB’s ability to generate recurring commercial revenue depends on successful drug development and subsequent commercialization or partnering. Specific, company-reported details on current reve...
PILA PHARMA AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.13M | 775.00K | 1.46M | 1.88M | 719.23K |
| Gross Profit | -6.82M | -8.12M | 1.46M | 1.88M | 680.94K |
| EBITDA | -15.92M | -10.11M | -8.81M | -26.76M | -17.16M |
| Net Income | -16.86M | -11.24M | -9.93M | -26.78M | -17.21M |
Balance Sheet | |||||
| Total Assets | 16.22M | 6.22M | 8.46M | 10.89M | 31.81M |
| Cash, Cash Equivalents and Short-Term Investments | 15.90M | 4.89M | 5.95M | 7.24M | 28.21M |
| Total Debt | 0.00 | 0.00 | 773.08K | 0.00 | 0.00 |
| Total Liabilities | 1.43M | 963.00K | 1.79M | 1.36M | 1.51M |
| Stockholders Equity | 14.78M | 5.26M | 6.66M | 9.53M | 30.30M |
Cash Flow | |||||
| Free Cash Flow | -9.19M | -7.82M | -4.85M | -9.09M | -9.36M |
| Operating Cash Flow | -9.19M | -7.82M | -4.85M | -9.09M | -9.36M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 20.19M | 6.76M | 3.56M | -11.88M | 35.67M |
PILA PHARMA AB Technical Analysis
Positive
2.20
Price Trends
1.47
Positive
1.49
Positive
1.59
Positive
Market Momentum
0.19
Negative
57.17
Neutral
73.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PILA, the sentiment is Positive. The current price of 2.2 is above the 20-day moving average (MA) of 1.75, above the 50-day MA of 1.47, and above the 200-day MA of 1.59, indicating a bullish trend. The MACD of 0.19 indicates Negative momentum. The RSI at 57.17 is Neutral, neither overbought nor oversold. The STOCH value of 73.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:PILA.
PILA PHARMA AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | kr89.77M | -4.32 | -145.63% | ― | -71.19% | -23.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr69.00M | -2.18 | -177.45% | ― | ― | 0.22% | |
44 Neutral | kr82.87M | -1.87 | -2775.09% | ― | 115.26% | -230.43% | |
42 Neutral | kr83.06M | -1.25 | -62.21% | ― | ― | 58.15% |
* Healthcare Sector Average
SE:PILA
PILA PHARMA AB
1.95
-0.41
-17.37%
SE:ONCOZ
OncoZenge AB
3.59
-1.67
-31.70%
SE:ACE
Ascelia Pharma AB
0.60
-3.16
-83.99%
SE:MODTX
Modus Therapeutics Holding AB
0.40
-0.09
-18.69%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.